Sarepta Therapeutics has shared initial clinical data on two siRNA candidates, delivering an early look at the wisdom of its decision to bet big on Arrowhead Pharmaceuticals’ pipeline.
Investing.com - Barclays reiterated an Equalweight rating on Sarepta Therapeutics (NASDAQ:SRPT) shares with a $20.00 price target. The stock currently trades at $23.77, rebounding from its previous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results